Published online Jul 31, 2013.
https://doi.org/10.4306/jknpa.2013.52.4.253
Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I) : Initial Choice of Antidepressant Treatment
Abstract
Objectives
The aim of this study is to establish Korean pharmacological treatment guidelines for the initial choice of antidepressant for treatment of moderate or severe depression.
Methods
The process for establishment of guidelines involved determination of important key questions, selection of 12 international and domestic clinical practice guidelines for depression, drawing of recommendation drafts, and peer review.
Results
Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRI), and noradrenergic and specific serotonergic antidepressants (NaSSA) were strongly recommended as the first-line antidepressants for treatment of moderate or severe depression. SSRIs were weakly recommended for patients who had problems with tolerability. Consideration of not only efficacy but also provisional adverse effects, drug-drug interactions, history of treatment response, preference, acceptability, cost, comorbid illnesses, and other factors in the choice of first-line antidepressants was strongly recommended. The treatment recommendations for specific clinical features of depression were as follows. SSRIs were weakly recommended for atypical depression. Augmented use of antipsychotics to antidepressants was strongly recommended for psychotic depression. Bupropion and SSRIs were weakly recommended for seasonal depression.
Conclusion
The results of this study may contribute toward improving the quality of depression treatment by providing clear and definite recommendations for the initial choice of antidepressant for treatment of moderate or severe depression.
Fig. 1
Searching and selection of clinical practice guidelines for depression.
Table 1
Twelve clinical practice guidelines for depression after the process of searching and selection
The authors have no financial conflicts of interest.
Acknowledgments
This study was supported by a grant of the Korean Health 21 Care Technology R & D Project, Ministry of Health and Welfare, Republic of Korea (A102065).
References
-
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. In: Global burden of disease and risk factors. Washington (DC): World Bank; 2006.
-
-
Lee MS, Lim SW, Cha JH, Chung SK, Kim KS, Kasper S. the Executive Committee for the Korean Medication Algorithm Project for Major Depressive Disorder. The development of the Korean medication algorithm for major depressive disorder. Psychiatry Investig 2005;2:60–69.
-
-
Clinical Research Center for Depression. Evidence-based Korean pharmacological treatment guideline for depression. Seoul: ML Communication; 2008.
-
-
Clinical Research Center for Depression. Evidence-based Korean non-pharmacological treatment guideline for depression. Seoul: ML Communication; 2009.
-
-
Clinical Research Center for Depression. Evidence-based Korean pharmacological treatment guideline for depression, revised edition. Seoul: ML Communication; 2012.
-
-
Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc 2006:359–363.
-
-
Kim SY, Kim NS, Shin SS, Kim DW, Ji SM, Lee SJ. In: ADAPTE: Manual for guildeline adaptation version 1.0. Seoul: National Clinical Research Coordination Center; 2009.
-
-
Steering Committee for Clinical Practice Guideline. Korean Appraisal of Guidelines for Research & Evaluation II. Seoul: Ministry of Health & Welfare and Korean Academy of Medical Science; 2009.
-
-
New Zealand Guidelines Group. Identification of Common Mental Disorders and Management of Depression in Primary Care. Wellington: Ministry of Health, New Zealand; 2008.
-
-
National Institute for Health and Clinical Excellence (NICE). Depression: the treatment and management of depression in adults (National Clinical Practice Guideline 90). London: National Institute for Health and Clinical Experience; 2009.
-
-
American Psychiatric Association (APA). Practice Guideline for the treatment of Patients with major depressive disorder. 3rd ed. Arlington: American Psychiatric Association (APA); 2010.
-
-
Professional Development & Quality Assurance prepared by a group of family physicians. Guideline on Management of Depression in Primary Care Hong Kong. 2009.
-
-
Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725–733.
-
-
Texas Department of Mental Health and Mental Retardation (TDMHMR) in collaboration with Texas universities. Texas Medication Algorithm Project Procedural Manual - Major Depressive Disorder Algorithms. 2008.
-
-
Korean Medication Algorithm Project for Depressive Disorder. Korean Medication Algorithm for Depressive Disorder 2008. Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology; 2008.
-
-
Ayuso-Gutiérrez JL. Depressive subtypes and efficacy of antidepressive pharmacotherapy. World J Biol Psychiatry 2005;6 Suppl 2:31–37.
-
-
Wijkstra J, Lijmer J, Balk FJ, Geddes J, Nolen WA. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Cochrane Database Syst Rev 2005:CD004044.
-
-
Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, Corral MR, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995;152:1765–1770.
-